Status:
COMPLETED
Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department
Lead Sponsor:
Methodist Health System
Conditions:
Angioedema
Eligibility:
All Genders
18-75 years
Brief Summary
Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE is defined as physical swelling of the deep skin layers or mucous membranes due to increased vascular permeability and leakage o...
Detailed Description
Angiotensin-converting enzyme inhibitor ACEi induced angioedema ACEi-AE most commonly affects the lips, mouth, face, upper airway, and less commonly the gastrointestinal tract. This condition may lead...
Eligibility Criteria
Inclusion
- •Patients must be ≥ 18 years old, be diagnosed with suspected ACEi-AE (with ACEi use). ACEi use is defined as patient-reported use or evidence indicating use listed in the chart.
Exclusion
- •Patients will be excluded if they have an allergy to TXA or any components of the formulation, present with an urticaria, have a personal or family history of hereditary angioedema, or received TXA administration in another department besides the ED.
Key Trial Info
Start Date :
November 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 23 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06096077
Start Date
November 30 2022
End Date
August 23 2023
Last Update
January 18 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Methodist Dallas Medical Center
Dallas, Texas, United States, 75203